Jonathan P. Mow
Net Worth

Last updated:

What is Jonathan P. Mow net worth?

The estimated net worth of Mr. Jonathan P. Mow is at least $5,690,669 as of 3 Nov 2021. He owns shares worth $3,589 as insider and has received compensation worth at least $5,687,080 in PhaseBio Pharmaceuticals, Inc..

What is the salary of Jonathan P. Mow?

Mr. Jonathan P. Mow salary is $812,440 per year as Pres, Chief Executive Officer & Director in PhaseBio Pharmaceuticals, Inc..

How old is Jonathan P. Mow?

Mr. Jonathan P. Mow is 60 years old, born in 1965.

What stocks does Jonathan P. Mow currently own?

As insider, Mr. Jonathan P. Mow owns shares in one company:

Company Title Shares Price per share Total value
PhaseBio Pharmaceuticals, Inc. (PHAS) Pres, Chief Executive Officer & Director 51,199 $0.07 $3,589

What does PhaseBio Pharmaceuticals, Inc. do?

PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure. The company is also developing PB1046, a vasoactive intestinal peptide analogue for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania. On October 23, 2022, PhaseBio Pharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

PHAS logo
PHAS
PhaseBio Pharmaceuticals, Inc.
$0.07

Jonathan P. Mow insider trading

PhaseBio Pharmaceuticals, Inc.

Transaction Date Security Shares Price per share Total value Source
Option
Common Stock 20,000 $1.24 $24,800
Option
Employee Stock Option (right to buy) 20,000 $1.24 $24,800
Option
Common Stock 20,000 $1.24 $24,800
Option
Employee Stock Option (right to buy) 20,000 $1.24 $24,800
Option
Employee Stock Option (right to buy) 10,000 N/A N/A
Option
Common Stock 10,000 N/A N/A
Option
Common Stock 19,000 N/A N/A
Option
Employee Stock Option (right to buy) 19,000 N/A N/A
Option
Employee stock option (right to buy) 19,131 N/A N/A
Option
Common Stock 19,131 N/A N/A
Option
Employee stock option (right to buy) 19,913 N/A N/A
Option
Common Stock 19,913 N/A N/A
Purchase
Common Stock 1,000 N/A N/A
Purchase
Common Stock 1,600 $3.85 $6,160
Purchase
Common Stock 1,600 N/A N/A
Purchase
Common Stock 2,900 N/A N/A
Purchase
Common Stock 2,900 $3.89 $11,267
Option
Series B Preferred Stock 310 N/A N/A
Option
Warrants to Purchase Series B Preferred Stock 310 N/A N/A

PhaseBio Pharmaceuticals key executives

PhaseBio Pharmaceuticals, Inc. executives and other stock owners filed with the SEC: